SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems
9.9.2019 09:55:00 EEST | Business Wire | Press release
SES today announced it will provide dedicated, private network connectivity from any vessel, airplane, enterprise, energy or government site in the world to Microsoft Azure via its unique multi-orbit satellite systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190908005042/en/
SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems (Photo: Business Wire)
As a partner of Azure ExpressRoute, SES will provide global reach and fibre-like high-performance to Azure customers via its complete portfolio of Geostationary Earth Orbit (GEO) satellites, Medium Earth Orbit (MEO) O3b constellation, global gateway network, and core terrestrial network infrastructure around the world. SES will offer Azure customers opportunities to leverage its satellite-enabled managed services to connect locations and sites in rural, remote and underserved locations, as well as vessels and airplanes out at sea and in the skies that previously did not have access to cloud services.
In addition to its global fleet of over 50 GEO satellites, SES also delivers managed data services over its proven O3b MEO satellite system, the only successful non-geostationary orbit (NGSO) broadband constellation. SES’s 20 O3b satellites comprise the only operational system today that can deliver fibre-equivalent, MEF-certified data connectivity services, and certified cloud connectivity services. The systems’ intelligent GEO- and MEO- orbit resilience that facilitate edge compute capabilities are key enablers in the seamless integration of high-performance satellite connectivity into Microsoft’s and their customers’ sites.
In addition, Azure customers also will be able to tap into SES’s groundbreaking next-generation MEO communications system, O3b mPOWER. Launching in 2021, O3b mPOWER will deliver ten times the throughput of the existing O3b constellation with unprecedented flexibility and dynamic control to help drive global cloud adoption everywhere.
“We believe that the economic and productivity benefits of the cloud should be easily available to all enterprise, maritime and aeronautical customers as well as government organisations, regardless of location. Now, as a Microsoft Azure ExpressRoute connectivity partner, we are expanding our strategic collaboration with Microsoft and extending intelligent cloud and edge services from Azure to the most underserved end points on the planet,” said JP Hemingway, CEO of SES Networks. “As the only satellite network services provider to operate a global, multi-orbit fleet utilising an extensive fleet of GEO and MEO satellites, SES stands ready to help Azure customers connect to any site at cloud scale, supporting critical enterprise workloads and offering an end-to-end network solution for emerging AI, IoT, video content services, and future applications to come.”
Ross Ortega, Partner, Product Manager of Azure Networking, Microsoft Corp. said, “We are collaborating with SES across a range of initiatives to build upon their expertise in satellite communications and increase connectivity to critical services and applications for customers in remote and underserved areas. This new collaboration between SES and Microsoft Azure Express Route further enables us to bring Azure to any business or government site.”
SES also announced today an expanded collaboration with Microsoft to benefit from Azure’s extensive cloud and AI capabilities to deliver one of the first broadcast-grade cloud services for media delivery. This builds on the broader strategic work between SES and Microsoft, as well as their shared common vision to reach everyone with intelligent cloud, media and network solutions.
More information on Azure ExpressRoute Data Sheet available here.
Follow us on:
Social Media
Blog
Media Library
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. SES Video delivers a full suite of innovative end-to-end value-added services for both linear and digital distribution, and includes the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190908005042/en/
Contact information
For further information:
Suzanne Ong
Public Relations
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom